Contact Information

160 Robinson Rd, #14-04
Sit Rd, SBF Center, Singapore 068914

European private equity firm Keensight Capital has recently secured €2.8B ($3B). They aim to invest this sum into promising ventures within the tech and healthcare sectors.

The important aspects of their plan can be summarized as follows:

  • Investment Target: Keensight Capital is primarily interested in profitable, high-growth companies. This discerning focus is expected to yield substantial returns in the long run.
  • Investor Demographics: Investors, both returning and newcomers, came from diverse regions: Europe, North America, the Middle East, and Asia. Increasingly, these investors demonstrate a preference for either niche-specialized firms or big asset managers offering a variety of investment options.
  • Company Size Preference: Keensight Capital actively pursues companies reporting revenues between €10M and €400M.
  • Market Outlook: Despite the unsettling current climate, Keensight’s Managing Partner, Jean-Michel Beghin, remains confident. According to him, their chosen segment continues to perform well.
  • Investment Strategy: There is a harmonious balance between buyers and sellers in the market, which facilitates asset trading. Keensight Capital’s focus is on high-cash-flow companies with reasonable leverage and stable revenues.

Keensight Capital has demonstrated its commitment to its strategy with recent investments in Inke (a pharmaceutical company), Nomios (a cybersecurity firm), and Buckaroo (a Dutch payment service provider).

client banner image


Leave a Reply

Your email address will not be published. Required fields are marked *